123 related articles for article (PubMed ID: 18839307)
1. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Malorni L; Shetty PB; De Angelis C; Hilsenbeck S; Rimawi MF; Elledge R; Osborne CK; De Placido S; Arpino G
Breast Cancer Res Treat; 2012 Dec; 136(3):795-804. PubMed ID: 23124476
[TBL] [Abstract][Full Text] [Related]
3. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
[TBL] [Abstract][Full Text] [Related]
4. Role of epidermal growth factor receptor in breast cancer.
Masuda H; Zhang D; Bartholomeusz C; Doihara H; Hortobagyi GN; Ueno NT
Breast Cancer Res Treat; 2012 Nov; 136(2):331-45. PubMed ID: 23073759
[TBL] [Abstract][Full Text] [Related]
5. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Lehmann BD; Bauer JA; Chen X; Sanders ME; Chakravarthy AB; Shyr Y; Pietenpol JA
J Clin Invest; 2011 Jul; 121(7):2750-67. PubMed ID: 21633166
[TBL] [Abstract][Full Text] [Related]
6. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide alleviates breast carcinoma via the inhibition of EGFR/ERK/ MMP-1 pathway with induction of apoptotic events.
Zhu W; Zhang F; Wang M; Meng S; Ren F
Acta Cir Bras; 2024; 39():e391624. PubMed ID: 38808816
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Management of Triple-Negative Breast Cancer (TNBC) in Jordan: A Retrospective Analysis.
Al Husban H; Al Rabadi A; Odeh AH; Abu Rumman K; Alkhawaldeh F; Noures H; Abo Ashoor M; Abu Rumman A; Atmeh M; Bawaneh M
Cureus; 2024 Jan; 16(1):e53053. PubMed ID: 38410339
[TBL] [Abstract][Full Text] [Related]
9. Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Ilie SM; Briot N; Constatin G; Ilie A; Beltjens F; Ladoire S; Desmoulins I; Hennequin A; Bertaut A; Coutant C; Causeret S; Ghozali N; Coudert B; Arnould L
Front Oncol; 2023; 13():1309890. PubMed ID: 38273853
[TBL] [Abstract][Full Text] [Related]
10. What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas-Current Status and Future Directions?
Maniar R; Loehrer PJ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254905
[TBL] [Abstract][Full Text] [Related]
11. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract][Full Text] [Related]
12. ERBB Receptors and Their Ligands in the Developing Mammary Glands of Different Species: Fifteen Characters in Search of an Author.
Morato A; Accornero P; Hovey RC
J Mammary Gland Biol Neoplasia; 2023 May; 28(1):10. PubMed ID: 37219601
[TBL] [Abstract][Full Text] [Related]
13. EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
Subham S; Jeppson JD; Worcester C; Schatmeyer B; Zhao J; Madan R; Lakis NS; Kimler BF; McGuirk JP; Chen RC; Stecklein SR; Akhavan D
Breast Cancer Res Treat; 2023 Jan; 197(1):57-69. PubMed ID: 36318382
[TBL] [Abstract][Full Text] [Related]
14. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer.
Li Y; Zhan Z; Yin X; Fu S; Deng X
Front Oncol; 2021; 11():731535. PubMed ID: 34778045
[TBL] [Abstract][Full Text] [Related]
16. The advance of adjuvant treatment for triple-negative breast cancer.
Ge J; Zuo W; Chen Y; Shao Z; Yu K
Cancer Biol Med; 2021 Aug; 19(2):187-201. PubMed ID: 34448553
[TBL] [Abstract][Full Text] [Related]
17. Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer.
Wang Z; Liu L; Li Y; Song Z; Jing Y; Fan Z; Zhang S
Front Oncol; 2020; 10():575317. PubMed ID: 33552956
[TBL] [Abstract][Full Text] [Related]
18. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
19. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
20. The impact of
Wang Y; Wu Z; Zhou L; Lu J; Wang Y; Lin Y; Xu S; Ye Y; Peng J; Zhang J; Yin W; Lu J
Gland Surg; 2020 Aug; 9(4):925-935. PubMed ID: 32953602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
